viewCello Health PLC

Issue of Equity

/**/ link{ color: #0563C1 }visited{ color: #954F72 } .k{size:595.3pt 841.9pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.k{}p.aa{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal;vertical-align:top}span.y{font-size:10.5pt;font-family:"Arial","sans-serif"; color:black;border:none windowtext 1.0pt;padding:0cm;background:white}p.ab{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center; vertical-align: top}span.w{font-size:10.5pt;font-family:"Arial","sans-serif";color:black; border:none windowtext 1.0pt;padding:0cm;background:white}p.ac{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: center; vertical-align: top}p.ad{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;line-height:normal;vertical-align:top}span.t{font-size:10.5pt; font-family:"Arial","sans-serif";color:black;border:none windowtext 1.0pt; padding:0cm;background:white}p.ae{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: justify; vertical-align: top} p.af{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.0pt; text-align: justify; vertical-align: top}table.ag{width:469.2pt;margin-left:-12.5pt;border-collapse:collapse}td.o{width:227.35pt;padding:0cm 5.4pt 0cm 5.4pt}span.p{font-size: 10.5pt;font-family:"Arial","sans-serif";color:black;border:none windowtext 1.0pt; padding:0cm;background:white}td.n{width:220.25pt;padding:0cm 5.4pt 0cm 5.4pt}span.l{font-size:10.5pt;font-family: "Arial","sans-serif";border:none windowtext 1.0pt;padding:0cm;background:white} /**/
RNS Number : 6052Z
Cello Health PLC
20 May 2019

20 May 2019

Cello Health plc

("Cello" or the "Company")


Issue of Equity


Further to the announcement released on 1 February 2017 regarding the acquisition of the assets of Defined Healthcare Research, Inc, and Cancer Progress, LLC ("Defined Health") by the Company, Cello today announces that the first deferred consideration payments to the vendors of Defined Health have now been settled.


To part satisfy the deferred consideration, the Company has applied for the admission of 320,243 new ordinary shares of 10 pence each in the Company ("Ordinary Shares") to trading on AIM, which is expected to occur on 24 May 2019.


Following admission, Cello's issued share capital will consist of 105,545,545 Ordinary Shares, of which 453,000 Ordinary Shares are held in treasury. The total number of current voting rights in the Company will therefore be 105,092,545 Ordinary Shares.


The above figure (105,092,545 Ordinary Shares) may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.




Cello Health plc

020 7812 8460

Mark Scott, Chief Executive

Mark Bentley, Group Finance Director


Cenkos Securities plc

020 7397 8900

Mark Connelly

Harry Hargreaves


Mark Court

020 7466 5000

Jamie Hooper

Sophie Wills


About Cello Health plc


We are a global healthcare-focused advisory Group comprised of a set of leading clinical, commercial advisory and digital delivery capabilities. We currently service 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients.


We enable clients to differentiate their propositions and drive brand success in ever more complex global markets. We deliver our services through nearly 1,000 highly skilled professionals utilising latest thinking, technology and digital solutions.


Cello Health plc delivers its services from an office network in the UK, USA, Germany and Asia, with hub offices in New York, Philadelphia, London, Berlin, Edinburgh, Farnham and Cheltenham.


For further information, please visit: https://cellohealthplc.com/


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Cello Health PLC

Price: 138

Market: AIM
Market Cap: £146.6 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

on 18/9/19


Pre-Close Trading Statement

4 days, 14 hours ago

Total Voting Rights

on 3/12/19

Holding(s) in Company

on 22/11/19

Holding(s) in Company

on 14/11/19

Total Voting Rights

on 13/11/19

Total Voting Rights

on 7/10/19


on 2/10/19